Biodyne makes liquid-based cytology (LBC) equipment for finding cancer early, along with consumables such as preservative solution, filters and slides, and earns royalties through its proprietary patented 'blowing' method, which uses air pressure to spread cells evenly. The method is registered in 29 countries, and the company has a long-term exclusive supply contract of more than 20 years with global diagnostics firm Roche. Roche first launched the 'VENTANA SP 400' device built on this technology in Japan in June 2025, at which point royalties and non-gynecological product revenue began to accrue; a March annual report confirmed the first full-year swing to profit, a May quarterly report confirmed a Q1 off-season loss, and an investment of about USD 6 million in a production plant near Hanoi, Vietnam is also under way. What stands out lately is that a hard-to-imitate exclusive moat with Roche, low debt and a thick cash cushion are strengths, but the surface P/E of 318x owes to the small profit of the first profitable year, and since the more appropriate yardstick, a forward 56x, is higher than peer diagnostics firms, whether it is justified turns on how fast royalties and Earlypap actually stack up in the numbers.
At-a-glance assessment financial health · growth · profitability · valuation
- Revenue rose 33.3% year over year, and the pace is quickening (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 5.4% lower than a year earlier.
- ROE is 1.9% (controlling-interest basis). It is below the sector average.
- Operating margin is 9.3%.
- The P/E sits above the sector median, reflecting elevated expectations.
Ownership & governance As of 2025-12-31
Largest shareholder Im Uk-bin 40.39% (individual)
Controlling bloc incl. related parties 41.85%
With the controlling bloc holding 42%, the ownership structure is stable.
🔎 In-depth analysis
- Biodyne earns money by making 'liquid-based cytology (LBC, a test in which collected cells are placed in a solution, spread thinly onto a slide and viewed under a microscope)' equipment and the consumables it uses (preservative solution, filters, slides, vials).
- Its core technology is the proprietary patented 'blowing method,' which uses air pressure to spread cells evenly, with patents registered in 29 countries including Korea and the United States.
- Its largest revenue source is a long-term exclusive supply contract of more than 20 years with global diagnostics firm Roche.
- In this structure Biodyne provides its IP (intellectual property) under license, Roche takes on mass production and sales, and pays royalties in return; when Roche first launched the LBC device 'VENTANA SP 400' built on Biodyne's technology in Japan in June 2025, royalty revenue and non-gynecological (beyond cervical) product revenue began to accrue.
- On top of this, it is growing 'Earlypap,' a self-collection kit with which women collect their own specimens, as a next-generation driver.
- The recent close is ₩8,580 and the market cap is ₩255.4 billion.
- The price sits below both the 20-day line (₩9,482) and the 60-day line (₩10,550).
- Trading below both its short- and mid-term moving averages, the trend is on the subdued side.
- The RSI (a supplementary gauge that weighs upward versus downward force over the past 14 days on a 0-100 scale) is 37.4, a neutral reading.
- The one-month change is -15.5%, the three-month change is -26.5%, and the position versus the 52-week high is -47.4%.
- Relative strength against the KOSDAQ is 49 (on a 1-99 scale, computed from returns versus the index over the past year with more weight on recent performance; higher means stronger than the market).
- That places it in roughly the top 51% for strength among all stocks.
- Over the past three months it lagged the index by 1.9%.
- Chart reading is best done together with volume and the dates of disclosures.
- On a confirmed full-year (2025) basis the P/E (how many times a year's net profit the share price is) is 300.00x and the P/B (how many times net assets the share price is) is 5.79x, which look very high on the surface.
- But this figure is divided by the small profit (net profit of ₩850 million) right after the company had just turned profitable at an inflection point, so a trailing (past confirmed) metric based on historical results can hardly be said to capture the company's real picture as is.
- The forward (future-based) P/E, reflecting a picture of earnings settled onto a normal track, shows an entirely different picture from the trailing 318x.
- ROE (how much is earned in a year on equity) is still low at 1.9%, but this is because the base is small in the first profitable year, and while the debt ratio (debt relative to equity) is 102%, most of the debt is operating-nature items, so the actual borrowing burden is light.
- A current ratio of 2,148% and cash-equivalent assets of about ₩26.8 billion, making the financial safety cushion thick, are clear strengths.
- Annual revenue rose from ₩4.1 billion in 2023 to ₩5.3 billion in 2024 to ₩7.0 billion in 2025, up an average of 31% a year over the past two years, and the pace is accelerating.
- Operating profit swung from losses of -₩2.0 billion in 2023 and -₩1.7 billion in 2024 to +₩650 million in 2025, and net profit turned positive alongside it at ₩850 million.
- This swing to profit was no accident but the result of royalties and non-gynecological product revenue actually starting to come in as Roche launched the 'VENTANA SP 400' in Japan in 2025.
- Right here is the basis for this year's forward earnings being set far more stably than last year's trailing.
- With a fixed demand source in the exclusive contract with Roche, and a license-and-royalty structure in which earnings follow as sales grow without additional facilities, revenue growth easily feeds straight through to earnings.
- By quarter, there is strong seasonality with revenue concentrated in Q4 (Q4 2025 revenue of ₩3.5 billion was half of annual revenue), so Q1 2026 revenue of ₩870 million and an operating loss of -₩400 million are an off-season pattern repeated every year and should be viewed separately from the annual flow.
- The core of the recent flow is growth-infrastructure investment and confirmation of regular results.
- The new facility investment amended and disclosed in March 2026 (a production plant near Hanoi, Vietnam, worth about USD 6 million, built in 2026 and operational in 2027) is a mass-production base for the Earlypap self-collection kit and a foundation for mid-to-long-term capacity (CAPA) expansion.
- The March annual report confirmed the first full-year swing to profit, the May quarterly report confirmed a Q1 off-season loss, and in May an investor relations (IR) session was held to explain the Roche collaboration and Earlypap strategy directly.
- The point to watch is confirming, through subsequent quarterly reports, the process by which supply contracts and royalty accrual feed into quarterly results and cash flow.
- This company's picture can be summed up as a 'structurally monopolistic business that has just begun to turn a profit.' The strengths are distinct.
- It has a hard-to-imitate moat in a 20-year-plus long-term exclusive contract with Roche, royalty and non-gynecological revenue has already begun to accrue with the VENTANA SP 400 launch, and with little debt and a thick cash cushion it has ample strength to endure growth investment.
- The surface P/E looks high at 318x, but this owes to the small profit of the first profitable year, and a forward 56x with earnings settled is the more appropriate yardstick for viewing this company.
- A point to weigh together is that a forward 56x is higher than peer diagnostics firms that have already settled into profit, which means whether it is justified turns on how fast the growth drivers of royalties and Earlypap actually stack up in the numbers.
- In sum, it is structured to strengthen as Roche revenue and non-gynecological and self-collection products accumulate into results quarter by quarter and seasonally adjusted annual earnings grow, while if that ramp is delayed, the heightened expectations can put a burden on the price.
🔎 Valuation vs peers Inconclusive
Rather than a simple industry code, diagnostics and in-vitro diagnostics (IVD) firms closer to the business substance (cancer-diagnostic testing equipment and diagnostic kits) were directly chosen for comparison: Classys (aesthetic medical devices, high-margin), Boditech Med (point-of-care IVD), and Genomictree (molecular-diagnostic early cancer detection).
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Classys | 24.77x | 5.91x | 23.86% |
| Boditech Med | 10.15x | 1.04x | 10.23% |
| Genomictree | — | 2.29x | -7.81% |
(a) Position versus the true comparison set: compared with Classys (P/E of 21.7x, ROE of 23.9%) and Boditech Med (P/E of 9.6x, ROE of 10.2%), which turn a profit and are settled, Biodyne's P/E of 357.7x and ROE of 1.9% look markedly expensive. On the other hand, as with still-loss-making Genomictree (P/B of 2.72x), diagnostics firms are hard to compare by P/E in early growth when earnings are small or absent. (b) Premium/discount: a P/B of 6.91x is higher than the comparison set, a range where future expectations are reflected in the price. That said, the structure of a long-term exclusive contract with Roche is hard to view as a simple discount. (c) Limits of trailing and the basis for forward: 2025 is an inflection point where it just turned profitable, so the confirmed-year P/E is overstated because earnings are small. As future figures, no official company outlook has been disclosed, so it can only be gauged with a DART seasonality approximation (2026 revenue of about ₩4.2 billion), and since forward earnings cannot be derived from this approximation, leaving it inconclusive is more appropriate than declaring it 'undervalued/overvalued.'
Earnings outlook company-stated · verified
| Type | Period | Revenue | Operating profit | Net profit |
|---|---|---|---|---|
| Next quarter | Q2 2026 | ₩1.1 billion | — | — |
Price history Close · MA20 · MA60
The latest close is ₩8,580 and the market capitalization is ₩255.4 billion. The price sits below its 20-day moving average (₩9,482) and below its 60-day moving average (₩10,550). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 37.4, a neutral level. The one-month change is -15.5%, the three-month change is -26.5%, and the position relative to the 52-week high is -47.4%. Relative strength versus the KOSDAQ is 49 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 49% of all stocks. Over the past three months it lagged the index by 1.9%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -1.94% / 6M -21.08% / 12M -45.22%
Key metrics vs sector median
Valuation
The P/E of 300.00x is above the sector median (22.72x). The P/B of 5.79x is above the sector median (1.61x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 1.9%, below the sector average (5.0%). The operating margin is 9.3%. The debt ratio is 102.0%, so the financial structure is moderate.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $2.7M | $3.5M | $4.7M | +33.32% ↑ faster |
| Operating profit | -$1.4M | -$1.1M | $432,299 | — |
| Net profit | -$657,314 | $7,138 | $564,414 | +7806.97% |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.5M | $8.1M | $2.7M | $3.5M | $4.7M |
| Operating profit | -$1.6M | $4.4M | -$1.4M | -$1.1M | $432,299 |
| Net profit | -$7.2M | $3.7M | -$657,314 | $7,138 | $564,414 |
| Revenue CAGR | 4-yr avg 16.90% | ||||
Revenue rose 33.3% year over year (2023 ₩4.1 billion → 2024 ₩5.3 billion → 2025 ₩7.0 billion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Over the 5 years on record, revenue compound annual growth (CAGR) is 16.9%. The two-year revenue CAGR is 31.1%. In the most recent quarter (Q1 2026), revenue was 5.4% lower than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- Revenue grew 33.3% year over year, a sign of growth.
Points to watch
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-03-03FilingNew facility investment, etc. (amendment) - about USD 6 million invested in a production plant near Hanoi, Vietnam, built in 2026 and operational in 2027Securing a mass-production base for the Earlypap self-collection kit lays a foundation for mid-to-long-term capacity expansion. Short-term costs rise, but it becomes the base for supplying non-gynecological and self-collection products going forward. Source
- 2026-05-15EarningsQ1 2026 quarterly report - revenue ₩870 million (-5.4% YoY), operating loss -₩400 millionQ1 is a seasonal off-season, so a loss is a normal pattern. Whether full-year profitability persists should be judged accounting for the Q4 concentration. Source
- 2026-05-15IRInvestor relations (IR) session held - explanation of Roche collaboration, VENTANA SP 400, and Earlypap strategyThe company directly shared the accrual of royalty and non-gynecological revenue and the direction of the self-collection kit business. A forum for confirming the progress of future revenue drivers. Source
- 2026-03-13Earnings2025 annual report - annual revenue ₩7.0 billion (+33.3%), operating profit +₩650 million swing to profitThe first confirmed full-year results with a swing to profit after two consecutive years of operating losses. The year in which Roche royalties and product revenue were first reflected meaningfully. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| 2025 annual revenue | ₩7.0 billion | 5,271→ 2025 27.08, 70.28 | Confirmed | link |
| Roche global exclusive supply and royalty structure | = + revenue | 20 approx. , IP | Confirmed | link |
| VENTANA SP 400 Japan launch | 2025 revenue | 2025-06-28 VENTANA SP 400 | Confirmed | link |
| 2026 annual revenue (approximate) | approx. ₩4.2 billion | — | Unverified | link |
Recent filings
- 2026-06-04OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-15OwnershipOwnership-change filing
- 2026-05-15Disclosure
- 2026-05-15PeriodicQuarterly report
- 2026-03-24Amended filing
- 2026-03-23Shareholders' meeting notice
- 2026-03-13PeriodicAnnual business report
- 2026-03-13Audit report
- 2026-03-06Shareholders' meeting notice
- 2026-03-03Amended filing
- 2026-02-19Shareholders' meeting notice
- 2026-02-19OwnershipOwnership-change filing
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.